Expanding on Data Surrounding Isatuximab Plus Pomalidomide/Dexamethasone in R/R Myeloma
Simon J. Harrison, MD, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.<br />
Simon J. Harrison, MD, director, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.
The main purpose of the study was to analyze the data from studies of isatuximab with pomalidomide (Pomalyst), and dexamethasone in patients with relapsed or refractory (R/R) multiple myeloma who have cytogenetic abnormalities contributing to their higher risk level. The study showed that the benefit of the regimen was maintained in high-risk patients, even though patients with cytogenetic abnormalities have worse outcomes overall.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
